Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo…
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed…
Report highlights emerging biotech innovators advancing new therapies, equity and investment across reproductive, chronic and mental health LONDON, Nov. 13,…
Congenital Heart Disease (CHD) is one of the most common birth defects, affecting approximately 1% of live births globally and…
Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease modelsSafety data from Phase 1 on…
XIAMEN, China, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of…
HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will…
November 02, 2025 09:00 ET | Source: Belite Bio, Inc MHRA response is based on the Phase 3 DRAGON interim…
Peer-reviewed (in-press) study finds serum-based antibody tests align, but milk results vary—calling for improved milk-specific diagnostics to strengthen herd surveillance…
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…